Drug intelligence / Profile preview

tozinameran + riltozinameran

Development stage: Approved
Lead developer: BioNTech
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

BNT162b2 bivalent (WT/OMI BA.1) is a nucleoside-modified mRNA vaccine developed by BioNTech and Pfizer to provide protection against COVID-19. It is a bivalent formulation containing 15 micrograms of mRNA encoding the spike protein of the original SARS-CoV-2 (Wuhan-Hu-1) and 15 micrograms of mRNA encoding the spike protein of the Omicron BA.1 variant. The vaccine utilizes lipid nanoparticle (LNP) technology to deliver the mRNA into host cells, where it is translated into spike proteins that trigger an immune response, including the production of neutralizing antibodies and activation of T cells. This bivalent version was developed as a booster to address waning immunity and the emergence of the Omicron variant.

Brand names: Comirnaty Original/Omicron BA.1
Other names: BNT162b2 (Original/Omicron BA.1)tozinameran/riltozinameranPfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.1)

Targets

PRR (Pattern recognition receptors)ACE2 (Angiotensin-converting enzyme 2)T-cell receptor and B-cell receptor recognizing SARS-CoV-2 spike protein

Beyond the preview

Go deeper on tozinameran + riltozinameran.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tozinameran + riltozinameran.

Explore the full profile